Form 8-K - Current report:
SEC Accession No. 0001493152-24-029295
Filing Date
2024-07-26
Accepted
2024-07-26 17:30:13
Documents
14
Period of Report
2024-07-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40554
  Complete submission text file 0001493152-24-029295.txt   256627

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ptix-20240724.xsd EX-101.SCH 3796
3 XBRL DEFINITION FILE ptix-20240724_def.xml EX-101.DEF 26655
4 XBRL LABEL FILE ptix-20240724_lab.xml EX-101.LAB 36749
5 XBRL PRESENTATION FILE ptix-20240724_pre.xml EX-101.PRE 25279
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5651
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 241148179
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)